ALIVE Study

The ALIVE Study leverages the pharmacology expertise at H3D and the genomics and computational biology capacity at Yemaachi to understand how drug metabolism varies across the continent, with the aim of better optimizing treatment regimens for African populations. Variations in drug metabolism are known to contribute significantly towards adverse drug reactions (ADRs). Africa carries a high burden of ADRs owing partly to the use of poorly-optimized drugs and high levels of genetic diversity. Because of the limited representation of Africans in trials worldwide (2% of clinical trial participants are people of African descent), very little is known about how drugs behave among African populations. This partnership will ultimately inform patient stratification and dose selection for phase II and III clinical trials for specific existing and new cancer medicines used in Africa

Partners: